logo
Marathon runners 'at risk of death' experts warn - alert after 13 deaths

Marathon runners 'at risk of death' experts warn - alert after 13 deaths

Daily Mail​27-04-2025
Ninety thousand runners will take part in London and Manchester marathons this week—and despite months of training the events are not without risk.
For those taking part in the gruelling 26.2 mile race, researchers warn that participating in such an extreme event could prove deadly.
Since the inaugural London Marathon in 1981, a total of 13 runners have died.
Experts say that a combination of genetic factors, race conditions and age can leave individuals in peril.
A major review of studies published in the British Medical Journal in 2019 found that the death rate for running a marathon was one fatality per 149,968 participants—meaning that someone is likely to die once every three years running the London Marathon.
An unnamed 36-year-old man died during the race in 2022, so, if the experts' calculations are correct, there could be a tragedy this year.
They also found that men were more than twice as likely to suffer catastrophic problems—and the average age of marathon runners who have died is 41.
The researchers concluded that the risk was small but deaths were more likely to occur in the last quarter of the race.
The most likely reason for fatality is a sudden cardiac arrest.
'The reason why [heart failure] happens with exertion, and, in particular with dehydration, is that there's a decrease in the blood volume,' says Dr Peter McCullough, a cardiologist at the Baylor University Medical Center at Dallas.
He explains that for younger marathon runners that die during a race it is likely due to a genetic problem.
'When someone suddenly dies in an athletic event, particularly in teenagers and those in their 20s and 30s, the most common cause is hypertrophic obstructive cardiomyopathy,' says Dr. McCullough
'This is a genetic abnormality of the proteins used by heart muscle cells.
'The heart becomes abnormally thick in one area and when the heart pumps, it has trouble ejecting blood past that thick point.'
As to why some deaths seem to occur at the end of the race, McCullough says, 'There's still a lot of circulating adrenaline so the heart is pumping very, very hard, but there's relatively little blood to fill it.'
Other factors include a build up of lactic acid, humidity and dehydration.
Experts say that there has been a rise in fatalities in recent years.
Dr Dan Tunstall-Pedoe, former London Marathon Medical Director, wrote in journal Sports Medicine that an increase in the sport's popularity was one contributor to the apparent increase in deaths.
He examined the records of documented sudden deaths across 650,000 marathon completions during that time, concluding that such risk in the London Marathon was one in 80,000 finishers.
Studies have shown though the survival rate after having a heart attack has increased significantly in the last two decades.
In a paper published in March, American researchers analysed data from 30million runners and found that the risk of dying from cardiac arrest at a race has decreased by approximately 50 per cent compared with 2000 to 2009.
'The incidence of cardiac arrest has remained relatively stable, apart from a slight unexplained rise after 2020, but despite that, the risk for death has markedly declined, by close to 50 per cent,' said Jonathan Kim, MD, cardiologist at Emory University in Atlanta, at the American College of Cardiology Scientific Session last month.
'We believe this is due to continued enhancements in the emergency action plans.'
According to Peak Performance, seven cardiac deaths occurred at the London Marathon between 1991 and 2003.
In 2007, David Rodgers died after completing his first London Marathon because he drank too much water.
Rogers, 29, collapsed at the end of the race and passed away in Charing Cross Hospital.
Five years later, a 30-year-old woman collapsed and died while running in the London Marathon—near St James' Park, on the final stretch of the 26.2-mile course.
A year later, another runner, Claire Squires, 30, suffered a cardiac arrest towards the end of the race and never regained consciousness.
An inquest heard the drug DMAA, a now-banned substance found in some nutrition supplements that was legal at the time, was in her system.
The coroner said she died of cardiac failure caused by extreme exertion, complicated by DMAA toxicity.
Captain David Seath, suffered a suspected cardiac arrest while running the 26.2-mile course in 2016 and later died in hospital. Seath was a fire support team commander in the 29 Commando Regiment Royal Artillery.
In 2018, Matt Campbell—who appeared on Masterchef: The Professionals—died after running the hottest-ever London Marathon.
Campbell collapsed during the marathon just four miles from the finish.
In the last death, the 36-year-old man collapsed just two miles from the finishing line.
Despite receiving immediate medical treatment and ambulance assistance within three minutes, the participant later died in the hospital.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer
Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer

Daily Mirror

time5 hours ago

  • Daily Mirror

Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer

Eli Lilly is increasing the UK price of its weight-loss drug Mounjaro Eli Lilly is set to significantly hike the UK price of its weight-loss and diabetes medication Mounjaro, with some dosages expected to see a staggering 170 percent increase starting from September. ‌ The pharmaceutical giant has justified the price surge as an effort to "address pricing inconsistencies compared with other developed countries, including in Europe" and to ensure equitable global contributions towards funding medical research. ‌ The sharpest rise will affect the month's supply of the drug's highest doses, which will soar from £122 to £330. Smaller doses will experience increases ranging from 45 to 138 percent. It comes after a man, 30, puts shoulder pain down to gym aches, then doctors ask where he'd like to die. ‌ Despite these changes, Lilly has assured that the NHS will not be affected by the new list prices, pledging to maintain the current rates to preserve uninterrupted patient access. Private healthcare providers, who also offer the medication, will face the new prices but have the option to negotiate confidential discounts directly with Eli Lilly. This development occurs amidst political debates in the US, where ex-president Donald Trump has lambasted what he deems "foreign freeloaders" for enjoying lower pharmaceutical costs while Americans bear much higher expenses. In one address, he highlighted obesity treatments, recounting how a friend in London acquired the "fat shot drug" at a fraction of the US cost, reports the Daily Record. Research from the Rand Corporation indicates that drug prices in the US are typically almost triple those in several other advanced nations. The pharmaceutical sector has been mobilising to combat the potential danger of a "most favoured nation" strategy, which could tie American pricing to international rates. ‌ Lilly highlighted that the UK was amongst the earliest markets to receive Mounjaro and emphasised that its initial focus had been on delivering the medication to diabetic patients swiftly. "At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation," the firm stated. Talks between pharmaceutical companies and the UK Government regarding NHS drug costs have grown increasingly fraught, with deliberations about modifications to a clawback levy on pharmaceutical sales extending well beyond agreed timelines. ‌ The Government's latest proposals featured plans to increase spending on medications, though industry chiefs voiced exasperation over the absence of specifics or clarity regarding whether this would involve purchasing additional medicines or paying elevated prices for current treatments. The National Institute for Health and Care Excellence (NICE) has endorsed Mounjaro for as many as 3.4 million individuals across England. Nevertheless, worries about cost-effectiveness resulted in an arrangement for a staged introduction, beginning with approximately 250,000 patients presenting the most urgent clinical requirements during the initial three years. NHS England has assured that the forthcoming price alterations will not impact the provision of the medication to qualified patients suffering from obesity or diabetes. "Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers," NHS England stated. The adjustments bring the UK's pricing more in line with the European mean, occurring amidst a period when drug manufacturers are acutely aware of how varying international prices might influence upcoming policy choices in the US.

Price of weight loss drug Mounjaro to rise - how much more users will pay
Price of weight loss drug Mounjaro to rise - how much more users will pay

Daily Record

time12 hours ago

  • Daily Record

Price of weight loss drug Mounjaro to rise - how much more users will pay

Eli Lilly will raise UK prices for Mounjaro by up to 170 percent to 'address pricing inconsistencies compared with other developed countries, including in Europe' Eli Lilly is sharply increasing the UK price of its weight-loss and diabetes drug Mounjaro, with the cost of some doses set to rise by as much as 170 percent from September. The pharmaceutical company said the move is intended to 'address pricing inconsistencies compared with other developed countries, including in Europe' and ensure a fairer global contribution to funding medical innovation. ‌ The most dramatic increase will see the month's supply of the highest doses of the drug jump from £122 to £330. Lower doses will rise by between 45 and 138 percent. However, Lilly stressed that the new list prices will not apply to the NHS, with the company continuing to supply the health service at the existing rate to avoid disrupting patient access. ‌ Private healthcare providers, who also prescribe the drug, will be subject to the increase but can negotiate confidential discounts with the company. ‌ The move comes against the backdrop of political pressure from the United States, where former president Donald Trump has criticised what he calls 'foreign freeloaders' benefiting from lower drug prices abroad while Americans pay substantially more. In a speech, he singled out obesity treatments, saying a friend in London had bought the 'fat shot drug' for far less than in the US. Research by the Rand Corporation suggests that US drug prices are, on average, almost three times higher than those in many other advanced economies. The pharmaceutical industry has been working to counter the potential threat of a 'most favoured nation' policy, which could peg American prices to those charged internationally. Lilly noted that the UK was one of the first markets where it launched Mounjaro and said its initial priority had been to get the medicine to diabetes patients quickly. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability. ‌ With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation,' the company said. Negotiations between drugmakers and the UK government over NHS medicine costs have been tense, with discussions about changes to a clawback tax on drug sales dragging past agreed deadlines. ‌ The government's most recent proposals included plans to spend more on medicines, but industry leaders expressed frustration at the lack of detail or clarity on whether this would mean buying more medicines or paying higher prices for existing ones. The National Institute for Health and Care Excellence (NICE) has recommended Mounjaro for up to 3.4 million people in England. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. ‌ However, concerns over affordability led to an agreement for a phased rollout, starting with around 250,000 patients who have the highest clinical need over the first three years. NHS England confirmed that the upcoming price changes would not affect how it provides the drug to eligible patients with obesity or diabetes. 'Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers,' it said. The changes place the UK price closer to the European average and come at a time when pharmaceutical companies are increasingly conscious of how international price differences could shape future US policy decisions.

ADHD drug can reduce patients' criminal behaviour
ADHD drug can reduce patients' criminal behaviour

Telegraph

time16 hours ago

  • Telegraph

ADHD drug can reduce patients' criminal behaviour

Drug treatment for ADHD can reduce patients' substance misuse, suicidal behaviour and criminal behaviour, a new study has found. Symptoms of ADHD (attention deficit hyperactivity disorder) can involve being inattentive, hyperactive and impulsive. The neurodevelopmental disorder is thought to affect about 5 per cent of children and 2.5 per cent of adults worldwide, while almost 2.5 million people in England have ADHD, according to the first estimates by the NHS. The study, which appeared in the British Medical Journal, examined 148,581 people in Sweden who had a new diagnosis of ADHD. Drug treatment for the disorder was associated with reduced rates of suicidal behaviour, substance misuse, transport accidents and criminality. 'These results provide evidence on the effects of ADHD drug treatment on important health-related and social outcomes that should inform clinical practice and the debate on the drug treatment of ADHD,' the report said. In June, a taskforce said NHS waiting lists for ADHD diagnosis and support have led to a 'significant growth in the use of private providers that are not regulated'. The ADHD taskforce, commissioned by NHS England with the support of the Government, published an interim report saying the system for diagnosing and managing the disorder needs to be overhauled. At the moment, ADHD assessment and treatment in England is provided by highly specialised doctors in secondary care. But the report warned: 'Inability to access NHS services has led to a significant growth in the use of private providers that are not regulated, resulting in two-tier access to services, diagnosis and treatment; one for those who can pay and another for those who cannot. 'This drives health inequalities and links to disproportionate impacts and outcomes in the education and justice systems, employment and health.' Wait times for NHS ADHD services 'have escalated and are unacceptably long' and demand is 'very likely' to continue to rise, the study warned. The NHS has launched publicly available data collection on ADHD referrals and waiting times to help local teams better understand how they are performing.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store